4MIT Technology Review — AI·
MIT Technology Review examines AI-driven drug discovery and the data loop challenge
MIT Technology Review publishes an analysis of AI applications in pharmaceutical drug discovery, framing the challenge around Eroom's Law — the observation that drug development costs have roughly doubled every nine years since the 1950s. The piece focuses on how closing feedback loops in AI-driven discovery pipelines could address the 10-15 year, high-cost development cycle. The article represents industry-level commentary on AI deployment in life sciences rather than a specific technical or product announcement.
Related guides (2)
Related events (8)
MIT Technology Review surveys AI-driven drug design for next-generation biologic medicines
MIT Technology Review examines how AI is being applied to the design of biologic medicines — protein-based therapies — where traditional drug development is expensive and failure-prone. The piece covers the use of AI to accelerate candidate identification and reduce attrition in the development pipeline. This is a high-level survey of an active application domain rather than a specific model or tool release.
MIT Technology Review traces the path from current AI agents to artificial superintelligence
MIT Technology Review publishes a commentary piece exploring the trajectory from today's narrow AI agents toward artificial superintelligence, using a multi-agent healthcare scenario to illustrate current coordination limitations. The piece argues that today's agents can exchange data but lack true coordination, framing this gap as a key obstacle on the path to more capable systems. The article represents mainstream technology press engaging with ASI timelines and multi-agent architectures.
Eli Lilly Commits Up to $2.75 Billion to Insilico Medicine for AI-Driven Drug Discovery
Eli Lilly agreed to pay up to $2.75 billion to Insilico Medicine, a Hong Kong biotech using generative AI across its drug-discovery pipeline, with an initial $115 million for exclusive rights to undisclosed pre-clinical drug candidates. Insilico's platform uses PandaOmics for target identification and Chemistry42 for molecule design, reducing the time from target identification to preclinical candidates from 5-6 years to roughly 18 months and screening far fewer compounds than conventional methods. The deal is the third between the companies and follows positive Phase 2a results for Rentosertib, an AI-discovered drug targeting idiopathic pulmonary fibrosis. No AI-discovered drug has yet received regulatory approval, and the key open question is whether AI-accelerated compounds will show higher clinical trial success rates than traditionally developed drugs.
MIT Technology Review: The emergence of web data infrastructure as an AI layer
MIT Technology Review examines the growing need for web data infrastructure to support enterprise AI, arguing that the web's unstructured and access-restricted nature creates a bottleneck for AI model training and deployment at scale. The piece frames web data acquisition and structuring as an emerging infrastructure layer analogous to earlier internet infrastructure layers. The analysis is relevant to practitioners tracking data supply chains for AI development.
MIT Technology Review: Leadership challenges in hybrid human-AI enterprises
MIT Technology Review examines how leadership teams are adapting to a projected 300% surge in AI agent adoption over the next two years. The piece focuses on the organizational and managerial implications of AI agents that autonomously coordinate complex tasks across tools and environments, distinguishing them from prior automation paradigms. The article addresses strategic and workforce management questions for enterprises integrating agentic AI.
MIT Technology Review AI Hype Index: 'Unsexy AI' edition
MIT Technology Review's recurring AI Hype Index column surveys recent AI developments framed around the gap between hype and practical reality, touching on robotics dexterity (1X), economic displacement concerns from leading economists, and other developments. The piece is a periodic editorial digest rather than a primary source. It provides a useful snapshot of which AI narratives are gaining or losing credibility in mainstream tech media.
MIT Technology Review: Advanced materials science as a foundation for next-gen AI infrastructure
MIT Technology Review examines how advanced materials science underpins AI hardware progress, arguing that improvements in processing power, memory, and energy efficiency depend on materials innovation below the semiconductor and data center layer. The piece frames materials R&D as a critical but underappreciated enabler of AI scaling. The article is a commentary piece rather than a primary research or product announcement.
MIT Tech Review analyzes Anthropic's latest AI research finding and its limits
MIT Technology Review examines a recent Anthropic research discovery, contextualizing what it does and does not demonstrate about AI systems. The piece situates the finding within Anthropic's broader research agenda, which includes investigations into AI model welfare and related frontier questions. As a tier-2 commentary piece, it offers critical framing rather than primary results.